VIOLIN Logo
VO Banner
Search: for Help
About
Introduction
Statistics
VIOLIN News
Your VIOLIN
Register or Login
Submission
Tutorial
Vaccine & Components
Vaxquery
Vaxgen
VBLAST
Protegen
VirmugenDB
DNAVaxDB
CanVaxKB
Vaxjo
Vaxvec
Vevax
Huvax
Cov19VaxKB
Host Responses
VaximmutorDB
VIGET
Vaxafe
Vaxar
Vaxism
Vaccine Literature
VO-SciMiner
Litesearch
Vaxmesh
Vaxlert
Vaccine Design
Vaxign2
Vaxign
Community Efforts
Vaccine Ontology
ICoVax 2012
ICoVax 2013
Advisory Committee
Vaccine Society
Vaxperts
VaxPub
VaxCom
VaxLaw
VaxMedia
VaxMeet
VaxFund
VaxCareer
Data Exchange
V-Utilities
VIOLINML
Help & Documents
Publications
Documents
FAQs
Links
Acknowledgements
Disclaimer
Contact Us
UM Logo

Vaccine Detail

Inactivated split Mem 71 Virus with SPT adjuvant
Vaccine Information
  • Vaccine Name: Inactivated split Mem 71 Virus with SPT adjuvant
  • Target Pathogen: Influenza virus
  • Target Disease: Influenza (flu)
  • Vaccine Ontology ID: VO_0004244
  • Type: Inactivated or "killed" vaccine
  • Status: Research
  • Antigen: Inactivated Mem 71virus (A/Memphis/l/71 x A/Bellamy/42 (H3N1) recombinant) (Deliyannis et al., 1998).
  • Adjuvant:
  • Immunization Route: subcutaneous injection
Host Response

Mouse Response

  • Host Strain: BALB/c
  • Vaccination Protocol: Mice were immunized subcutaneously on day 0 with 0.1 ml of vaccine containing various doses of split Mem 71 virus with or without adjuvant (Deliyannis et al., 1998).
  • Challenge Protocol: MIce were challenged intranasally with 10^4.5 plaque forming units (p.f.u.) of live Mem 71 influenza virus (Deliyannis et al., 1998).
  • Efficacy: Protection from subsequent influenza infection was assessed by examining the ability of vaccinated mice to clear a challenge dose of virus from their lungs by 3 days postinfection. Mice immunized with virus in SPT adjuvant had greater levels of viral clearance than in mice immunized without adjuvant (Deliyannis et al., 1998).
References
Deliyannis et al., 1998: Deliyannis G, Jackson DC, Dyer W, Bates J, Coulter A, Harling-McNabb L, Brown LE. Immunopotentiation of humoral and cellular responses to inactivated influenza vaccines by two different adjuvants with potential for human use. Vaccine. 1998; 16(20); 2058-2068. [PubMed: 9796065].